Abstract: The present disclosure relates to a deep learning-based method for predicting a high-dimensional and highly-variable cloud workload, including the following steps: Step S1: obtaining historical workload data of a cloud data center, and carrying out preprocessing; Step S2: on the basis of a raw data set, predicting a future workload of a central processing unit by using a deep learning based prediction algorithm for cloud workloads (L-PAW) integrating a top-sparse auto-encoder (TSA) and a gated recurrent unit (GRU), and transmitting a predicted result to a cloud service provider (CSP); and Step S3: determining, by the CSP, a resource allocation strategy according to the predicted result, such that the cloud data center achieves load balancing. The present disclosure realizes adaptive and effective workload prediction, thereby effectively improving the efficient resource allocation efficiency in cloud computing.

Abstract: Disclosed are an aromatic heterocyclic compound and an application thereof. The aromatic heterocyclic compound is represented by formula I, and the compound has good LSD1 enzyme inhibitory activity, and can be used as an LSD1 inhibitor for treatment of tumors etc.

Abstract: A solid dispersion, a preparation method therefor, and a solid formulation comprising same. The solid dispersion comprises compound A and a pharmaceutically acceptable matrix polymer, wherein the pharmaceutically acceptable matrix polymer includes an enteric high-molecular polymer and a non-enteric high-molecular polymer, and the compound A is 1-{(6-[(1-methyl)-4-pyrazolyl]-imidazo[1,2-a]pyridine)-3-sulfonyl}-6-[(1-methyl)-4-pyrazolyl]-1-hydro-pyrazolo[4,3-b]pyridine. The solid dispersion can significantly improve the solubility and dissolution stability of the compound A, prolong the supersaturation maintenance time of a drug, and further improve the bioavailability of the drug. The in vivo bioavailability of a solid formulation prepared from the solid dispersion meets the requirement of oral administration of the compound A.

Abstract: The present invention relates to a deep reinforcement learning-based cloud data center adaptive efficient resource allocation method. First, an operation (a scheduling job) is selected according to a score evaluated by critic (an evaluation operation) by using an actor parameterized policy (resource allocation). Then, a resource allocation policy is updated through gradient boosting, and a variance of a policy gradient is reduced by using an advantage function, to improve training efficiency; and wide simulation experiments are performed by using real data from a Google cloud data center. Compared with two advanced DRL-based cloud resource allocation methods and five classic cloud resource allocation methods, the method provided in the present invention has higher quality of service (QoS) in terms of a delay and a job dropout rate and has higher energy efficiency.

Abstract: The present disclosure relates to a fused ring pyrimidine amino compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically disclosed in the present disclosure are the compound shown in formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof, a metabolite thereof, a metabolic precursor thereof, or a prodrug thereof. The fused ring pyrimidine amino compound of the present application has good inhibitory activity against DDRs, particularly DDR2, and has a good therapeutic effect on tumors and fibrotic diseases, especially pulmonary inflammation and pulmonary fibrosis. Also disclosed in the present disclosure are a preparation method for the compound shown in formula I, and a use thereof.

Abstract: The present disclosure relates to a fused ring pyrimidine amino compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically disclosed in the present disclosure are the compound shown in formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof, a metabolite thereof, a metabolic precursor thereof, or a prodrug thereof. The fused ring pyrimidine amino compound of the present application has good inhibitory activity against DDRs, particularly DDR2, and has a good therapeutic effect on tumors and fibrotic diseases, especially pulmonary inflammation and pulmonary fibrosis. Also disclosed in the present disclosure are a preparation method for the compound shown in formula I, and a use thereof.

Abstract: The present invention relates to dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof. The inhibitor of the present invention is compound represented by general formula (I), or stereoisomer, pharmaceutically acceptable salt, prodrug, solvate, hydrate and crystal form thereof. The definition of each substituent is as described in the description and claims. The compound represented by general formula (I) of the present invention may inhibit bromodomain recognition protein and may be used for preparing medicament which regulates the apparent state of cells and treats series of diseases and symptoms which are mediated by the bromodomain recognition protein.

Abstract: A method of collecting radiation information of a turbine blade, the method including: 1) collecting a radiated light from the surface of the turbine blade, analyzing the radiated light using a spectrometer to calculate compositions and corresponding concentrations of combustion gas; 2) calculating an absorption coefficient of the combustion gas at different concentrations; 3) calculating a total absorption rate of the combustion gas at different radiation wavelengths under different concentrations of component gases; 4) obtaining a relationship between the radiation and a wavelength; 5) finding at least 3 bands with a least gas absorption rate; 6) calculating a distance between a wavelength of a strongest radiation point of the turbine blade and the center wavelength, and selecting three central wavelengths closest to the wavelength with the strongest radiation; and 7) acquiring radiation data of the turbine blade in the windows obtained in 6).

Abstract: The present invention relates to dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof. The inhibitor of the present invention is compound represented by general formula (I), or stereoisomer, pharmaceutically acceptable salt, prodrug, solvate, hydrate and crystal form thereof. The definition of each substituent is as described in the description and claims. The compound represented by general formula (I) of the present invention may inhibit bromodomain recognition protein and may be used for preparing medicament which regulates the apparent state of cells and treats series of diseases and symptoms which are mediated by the bromodomain recognition protein.

Abstract: A method of collecting radiation information of a turbine blade, the method including: 1) collecting a radiated light from the surface of the turbine blade, analyzing the radiated light using a spectrometer to calculate compositions and corresponding concentrations of combustion gas; 2) calculating an absorption coefficient of the combustion gas at different concentrations; 3) calculating a total absorption rate of the combustion gas at different radiation wavelengths under different concentrations of component gases; 4) obtaining a relationship between the radiation and a wavelength; 5) finding at least 3 bands with a least gas absorption rate; 6) calculating a distance between a wavelength of a strongest radiation point of the turbine blade and the center wavelength, and selecting three central wavelengths closest to the wavelength with the strongest radiation; and 7) acquiring radiation data of the turbine blade in the windows obtained in 6).

Abstract: This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumors associated with abnormal protein tyrosine kinase.

Abstract: This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumours associated with abnormal protein tyrosine kinase.

Abstract: This application relates to micelle-forming poly(ethylene oxide)-block-poly(ester) block copolymers having reactive groups on both the poly(ethylene oxide) block and the poly(ester) block therein. The biodegradability of these copolymers and their biocompatibilities with a large number of bioactive agents make them suitable as carriers for various bioactive agents. The bioactive agent, such as DNA, RNA, oligonucleotide, protein, peptide, drug and the like, can be coupled to the reactive groups on the polyester block of the copolymer. A variety of targeting moieties can be coupled to the reactive group on the poly(ethylene oxide) block for targeting the bioactive agent to a particular tissue. The application also relates to a composition and method of use thereof for delivering bioactive agents.

Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.

Abstract: A technique for providing multiple Fiber Channel frames in one frame-mapped GFP transport frame. GFP conventions are followed, except that a Distributed Delimiter marks each Fiber Channel frame in the payload of GFP transport frame. The Distributed Delimiter has a Fixed Pattern field which varies distinctly from the special K28.5 character which indicates Fiber Channel Ordered Sets and has a Frame Length field to indicate the length of the Fiber Channel frame.

Abstract: A technique for providing multiple Fibre Channel frames in one frame-mapped GFP transport frame. GFP conventions are followed, except that a Distributed Delimiter marks each Fibre Channel frame in the payload of GFP transport frame. The Distributed Delimiter has a Fixed Pattern field which varies distinctly from the special K28.5 character which indicates Fibre Channel Ordered Sets and has a Frame Length field to indicate the length of the Fibre Channel frame.

Abstract: A technique for providing multiple Fibre Channel frames in one frame-mapped GFP transport frame. GFP conventions are followed, except that a Distributed Delimiter marks each Fibre Channel frame in the payload of GFP transport frame. The Distributed Delimiter has a Fixed Pattern field which varies distinctly from the special K28.5 character which indicates Fibre Channel Ordered Sets and has a Frame Length field to indicate the length of the Fibre Channel frame.

Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.

Abstract: A technique for providing multiple Fibre Channel frames in one frame-mapped GFP transport frame. GFP conventions are followed, except that a Distributed Delimiter marks each Fibre Channel frame in the payload of GFP transport frame. The Distributed Delimiter has a Fixed Pattern field which varies distinctly from the special K28.5 character which indicates Fibre Channel Ordered Sets and has a Frame Length field to indicate the length of the Fibre Channel frame.